Recently, a clinical study revealed that a MUC1/CD3 bispecific antibody conjugated CIK (cytokine-induced killer) cell therapy could lead to the complete response in primary hepatocellular carcinoma (HCC) patients when combined with PD1 inhibitor treatment [42]. Here, MUC1 is linked to hepatocellular carcinoma.